乌龙制药 URGN 深 沪
已收盘 05-22 16:00:00 美东时间
28.89
-0.990
-3.31%
华盛通- 最 高32.37
- 今 开29.84
- 成交量 33.63万股
- 最 低 23.63
- 昨 收 29.88
- 总市值 65.56万
- 52周最高 32.37
- 市盈率 静 --
- 换手率 1482.13%
- 52周最低 4.36
- 委 比 63.64%
- 总股本 2.27万
- 历史最高 69.568
- 量 比 0.53
- 振 幅 29.25%
- 历史最低 1.10
- 每 手 1
- 风险率 5.11%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UroGen Pharma: Q4 Earnings Insights
The Q4 earnings report for UroGen Pharma (NASDAQ:URGN) was released on Monday, ...
03-02 21:02
Earnings Scheduled For March 2, 2026
Companies Reporting Before The Bell • Zymeworks (NASDAQ:ZYME) is expected to re...
03-02 19:11
UroGen Pharma Earnings Preview
UroGen Pharma (NASDAQ:URGN) is set to give its latest quarterly earnings report...
02-28 02:02
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
Cardinal Health周四盘前下跌 19亿美元收购交易致股价下挫
美东时间周三08：48，Cardinal Health（CAH）股价下跌0.2%。该公司周三宣布以19亿美元收购医疗技术公司UroGen Pharma（URGN），引发股价盘中一度下跌4.2%，最终收跌2.7%至102.45美元。这笔全现金交易对URGN的估值达每股16美元，较其周二收盘价溢价14%。 海量资讯、精准解读，尽在新浪财经APP 责任编辑：张俊 SF065
2025-08-14 20:50
FDA顾问委员会否决膀胱癌药物 乌龙制药股价暴跌近半
周三，乌龙制药(UroGen Pharma，URGN.US)股价暴跌约47%，此前美国食品药品监督管理局(FDA)顾问委员会对该公司的膀胱癌疗法UGN-102(丝裂霉素)投下反对票，这款药物目前正在美国接受监管审查。 在针对膀胱内注射溶液的风险获益比问题上，FDA肿瘤药物顾问委员会(ODAC)以4票赞成、5票反对的结果否决了该药物。这对正寻求UGN-102美国批准的乌龙制药来说是重大挫折。 去年10月，FDA受理了该公司关于UGN-102用于治疗复发性低级别中危非肌层浸润性膀胱癌(LG-IR-NMIBC)的新药申请(NDA)，并将2025年6月13日定为目标行动日期。 乌龙制药医疗主管马克·舍...
2025-05-22 08:36
D. Boral Capital Maintains Buy on UroGen Pharma, Maintains $25 Price Target
D. Boral Capital analyst Jason Kolbert maintains UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $25 price target.
2025-03-10 22:36
UroGen Pharma Q4 2024 GAAP EPS $(0.80) Misses $(0.68) Estimate, Sales $24.57M Miss $25.63M Estimate
UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.68) by 17.65 percent. This is a 11.11 percent decrease over losses of $(0.72) per share from
2025-03-10 20:01
Earnings Scheduled For March 10, 2025
Companies Reporting Before The Bell • Franco-Nevada (NYSE:FNV) is expected to r...
2025-03-10 16:32
UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041
Once issued, this patent provides U.S. intellectual property coverage of UroGen's RTGel® technology with medac lyophilized mitomycin formulation, covering UGN-103 and UGN-104 development programs until December
2024-09-16 20:26
